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Abstract 
Antibody therapeutics against different target antigens are widely used in the 
treatment of different malignancies including ovarian carcinomas, but this disease still 
requires more effective agents. Improved understanding of the biological features, 
signaling pathways, and immunological escape mechanisms involved in ovarian 
cancer has emerged in the past few years. These advances, including an appreciation 
of the cross-talk between cancer cells and the patient’s immune system, have led to 
the identification of new targets. In turn, potential antibody treatments with various 
mechanisms of action, including immune activation or toxin-delivery, that are 
directed at these targets have been developed. Here, we identify established as well as 
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 04
:07
 09
 A
ug
us
t 2
01
6 
 2 
 
novel targets for antibodies in ovarian cancer, and discuss how they may provide 
fresh opportunities to identify interventions with enhanced therapeutic potential. 
Keywords 
ovarian cancer, antibodies, immunotherapy, tumor-associated antigen, immune 
checkpoint, vaccine, tumor-promoting molecule, molecular-targeting, clinical trials 
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Introduction 
It is estimated that ~ 22,280 American women will receive new diagnoses of ovarian 
cancer in 2016, and an estimated 14,240 deaths from the disease will occur in this 
year.
1
 Standard therapy is a combination of maximal surgical cytoreductive and 
taxane- and platinum-based chemotherapeutic agents. Nevertheless, relapse is 
common after first-line treatment. Despite investigations of novel chemotherapeutic 
regimes, targeted and other therapies, there have been no significant improvements in 
clinical outcomes or cure rates, with current 5-year overall survival rates at only 
45%.
2
 
Given that ovarian cancer is known to be immunogenic and high numbers of 
infiltrating immune cells, including effector cells such as T cells and macrophages, 
are associated with improved survival rates,
3
 antibody-based therapies are thought to 
offer promise. Monoclonal antibody immunotherapies may redirect these effector 
cells against cancer and mediate specific and potent anti-tumor immune responses, 
with the aim of restricting tumor growth and improving disease course. Here, we 
focus on established and emerging new targets for antibody treatments in ovarian 
carcinoma, and we discuss monoclonal antibodies that have been studied in patients 
with this disease. 
Targets for Antibody Treatments 
Tumor-associated antigens 
Tumor-associated antigens (TAAs) are surface-associated molecules or receptors 
expressed by tumor cells, which have limited or no expression on normal cells. Often 
TAAs are involved in the activation of signaling transduction pathways that support 
unregulated growth or division of cancer cells. This specificity in expression and role 
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in pro-tumoral functions make TAAs promising antibody targets, allowing tumor cells 
to be specifically marked for immune cell destruction or blockade of tumor-associated 
signaling, which impedes malignant function, invasiveness and survival. 
CA125 
CA125 (MUC16), an extremely large, 2500-5000 kDa, mucin-like surface 
glycoprotein, is expressed in greater than 95% of non-mucinous stage III/IV epithelial 
ovarian cancers (EOCs) and in 50-80% of ovarian tumors overall. CA125 is thought 
to support tumor-associated immune escape in the tumor microenvironment (TME).
4, 
5
 High CA125 expression correlates with protection against cytolytic killing by 
natural killer (NK) cells, which is linked to reduced activating immune synapses 
between NK and target cells, and thus decreased cell adhesion.
5
 This may be because 
the NK synaptic cleft requires a distance of 10-50 nm between NK and cancer cells, 
which is thought to be disrupted by the large (up to 24,000 amino acid) protein 
backbone of CA125 that can protrude from ovarian tumor cells by up to 1-5μm. 5 
However, given the heterogeneity of the size of CA125 reported, which may be a 
result of the biological source of the molecules studied or differing biological 
methods used to characterize them,
6
 or significant variation in the extent of protein 
glycosylation,
5
 the degree of immune escape as well as other biological functions of 
CA125-expressing tumor cells may vary. 
It has also been suggested that inhibition may be due to a CA125-induced reduction in 
NK cell expression of the Fc activating receptor, CD16.
4
 In fact, NK cells from 
patients with EOCs have shown significant reduction in CD16 expression compared 
to NK cells from healthy donors. A down-regulation of activatory receptors, such as 
CD16, leads to relative predominance of NK cell inhibitory receptors, and thus NK 
cells fail to respond to tumor cells, allowing tumor evasion of the innate immune 
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response.
4
 Similarly, a down-regulation of CD16 may also lead to ovarian tumor cell 
evasion of the adaptive immune system, by prevention of CD16 binding to host 
tumor-specific immunoglobulins.
4
 These immunoediting mechanisms are likely to 
potentiate the progression and proliferation of ovarian tumors. 
CA125 is also thought to facilitate pro-tumor cell-cell interactions in an N-linked 
glycan dependent manner.
7
 CA125 on the surface of ovarian tumor cells binds to the 
glycoprotein mesothelin, expressed on epithelial cells (described below), with a high 
Kd of 5-10 nM. This cell adhesion is likely to occur in the peritoneum of patients with 
ovarian cancer, and may provide the first step to metastasis of tumor cells, likely 
reinforced by recruitment of CD44, β-1 integrins and other adhesion molecules.7 
CA125 is shed from ovarian cancer cells into the blood and peritoneal cavity upon 
proteolytic cleavage. CA125 serum levels are known to correlate with tumor 
progression and recurrence. Thus, monitoring serum CA125 levels is a well-
established and useful surrogate for evaluating response to conventional 
chemotherapeutic and surgical treatments, and is routinely used for surveillance in 
follow-up.
8
 
MUC1 
MUC1 is an epithelial mucin, comprising a heavily glycosylated transmembrane 
glycoprotein, overexpressed in many carcinomas, including 90% of EOC cells.
9
 The 
subunit, MUC1-C, is thought to contribute to malignant cellular transformation by 
regulating gene transcription, blocking stress-induced apoptosis and necrosis, and 
attenuating death receptor activation. The extracellular domain consists of mucin-like 
tandem repeats, which are differentially glycosylated between malignant and normal 
cells, resulting in the exposure of differing peptide epitopes. MUC1 expression in 
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cancer facilitates tumor invasive growth and metastasis. It can act in both an anti-
adhesion manner, resulting in the release of cells from tumor nests and increased 
metastasis, and a pro-adhesion manner, leading to malignant spread.
9, 10
 Cancer cells 
also exploit MUC1 interactions with a number of growth receptors to promote 
survival. High expression of MUC1 by tumor cells leads to reduced cytotoxic killing 
by T and NK cells. This may be due to the large and complex nature of this TAA, 
which results in masking of extra-cellular domains for immunosurveillance and 
mediates tumor cell escape.
9
 
Humoral and cellular responses against MUC1 have been observed in cancer 
patients.
11
 Anti-MUC1 antibodies have been shown to inversely correlate with 
ovarian carcinoma risk factors,
12
 thus supporting MUC1 as a promising target for 
therapy. 
EpCAM 
EpCAM (CD326) is a type I transmembrane glycoprotein that is highly expressed 
across all ovarian cancer subtypes. Its expression is maintained in metastatic 
disease,
13
 and EpCAM overexpression is prognostic of reduced overall survival (OS) 
in ovarian cancer.
14
 Expression on epithelial carcinomas is at the cell surface, whereas 
in normal epithelial tissues, EpCAM is expressed basolaterally and is protected by 
tight junctions, making this an attractive target for anti-cancer therapy. 
However, EpCAM is reported to have mixed functions in tumor formation, motility 
and metastasis. EpCAM-expressing cells make homophilic interactions, forming 
aggregated clusters, which may be important in the structure of a tumor, but may also 
impede invasion and metastasis. In contrast, EpCAM inhibits E-cadherin mediated 
cell-cell interactions, and therefore, in this manner, may promote cell motility and 
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metastasis.
15
 It is likely that these contrasting functions may be induced differentially 
depending on the TME, and there is little evidence to ascertain how these dynamics 
affect ovarian cancer. 
Folate Receptor-α 
Folate receptor-α (FRα) is a 38 kDa glycosylphosphatidylinositol (GPI)-anchored 
membrane protein, which can transport folate via receptor-mediated endocytosis. It is 
overexpressed in 80-90% of EOCs.
16
 The level of FRα expression on cancer cells, has 
been shown to correlate with the histologic grade and stage of ovarian cancer.
17-19
 
Overexpression is significantly higher in serous ovarian carcinoma than in mucinous 
carcinomas and other epithelial histotypes. FRα expression is thus considered a 
marker of tumor aggressiveness. Although there is conflicting data reported in the 
literature, when all histotypes of ovarian cancer are studied
18
 elevated tumor 
expression of FRα is associated with lower disease-free interval (DFI) and poor OS in 
patients with serous ovarian carcinoma.
19
 
A role for FRα in tumor cell survival and progression is demonstrated by the 
preservation of FRα expression on recurrent tumors and metastatic foci.18 It is thought 
that over-expression of FRα by cancer cells may support tumor progression by 
modulating folate uptake and regulatory signals, resulting in increased proliferation of 
malignant cells through enhanced DNA synthesis.
20
 Knockdown of FRα expression 
on the SKOV-3 ovarian carcinoma cells resulted in inhibition of folate-mediated cell 
proliferation, migration and invasion.
17
 FRα may also facilitate chemo-resistance in 
ovarian carcinoma.
19-21
 Higher tissue FRα expression correlates with poor 
chemotherapeutic response in patients with serous ovarian carcinoma. Lower levels of 
apoptosis in vitro were induced by cisplatin, paclitaxel or topotecan treatment of 
OVACR-3 cells expressing high levels of FRα, compared to low-expressing control 
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cells. The mechanism of this apoptotic escape is thought to be via FRα-mediated 
down-regulation of caspase 3 and 7 apoptosis pathways, increased expression of the 
anti-apoptotic molecule, Bcl-2 and decreased expression of the pro-apoptotic 
molecule, Bax.
19
 Furthermore, inhibition of the tumor suppressor gene, caveolin-1, by 
FRα is thought to support ovarian carcinoma progression.20 In vitro studies using 
IGROV1 and SKOV3 ovarian cancer cells demonstrated that FRα expression levels 
correlate with the down-regulation of caveolin-1 expression, allowing tumor-
progression by promoting cell cycle progression and anchorage-independent growth; 
functions which are normally inhibited by caveolin-1.
22
 
FRα is considered to be a promising target for anti-cancer therapies23, since it is 
highly expressed on carcinoma cells, but has limited expression on normal tissues; 
expression is found only at low levels on the retina, placenta, intestine and choroid 
plexus, at the luminal surface of the kidney and lung, which are not accessible to the 
bloodstream.
24
 Furthermore, it has been reported that patients with ovarian cancer 
demonstrate increased immunity to FRα compared to healthy controls, suggesting that 
this is a sensible target for immunotherapies.
25
 
Mesothelin 
Mesothelin is a 40 kDa immunogenic cell surface protein that is highly expressed, 
particularly in non-mucinous subtypes of ovarian cancer cells, with normal tissue 
expression restricted to mesothelial cells.
26
 As described above, an interaction 
between CA125 on tumor cells and mesothelin in the peritoneum may be involved in 
the metastatic process. Furthermore, co-expression of mesothelin and CA125 on 
tumor cells is thought to lead to clustering of tumor cells at metastatic sites, as 
CA125-expressing cells have demonstrated significantly higher homotypic adhesion 
interactions compared to CA125-negative tumor cells.
7
 Such multicellular spheroids 
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have been observed in the ascitic fluid of patients with ovarian cancer, and these have 
been shown to adhere to human mesothelial cell layers. This suggests a role for 
CA125-mesothelin mediated cell clusters in peritoneal dissemination of disease.
27
 
Although adhesion is partly reduced by β-1 integrin inhibition, molecules such as 
mesothelin are also likely to be important.
7
 
Consistent with its proposed role in tumor metastasis, high expression of mesothelin 
in ovarian cancer has been associated with more advanced disease, and worse 
progression-free survival (PFS) and OS.
28
 Additionally, high levels of mesothelin 
expression correlate with resistance to chemotherapy.
28
 
Epidermal growth factor receptor family 
The epidermal growth factor receptor (EGFR) family comprises four structurally-
related tyrosine kinase receptors expressed on the apical surface of epithelial cells; 
ErbB1/HER1 (commonly known as EGFR or HER1), ErbB2/HER2, ErbB3/HER3, 
and ErbB4/HER4. Upon ligand binding, receptor dimerization occurs, followed by 
tyrosine auto-phosphorylation and subsequent activation of EGFR signaling. 
Downstream signaling is known to augment cellular responses, including cancer cell 
proliferation, motility, invasion, and survival.
29
 
HER1 is the most widely studied EGFR family member involved in ovarian cancer. 
Increased HER1 expression is an early event in ovarian cancer development, and thus 
may be involved in neoplasia.
29
 HER1 amplification analysis in tissue microarrays 
showed that HER1, but not HER2, expression was greater in higher grade ovarian 
carcinomas.
30
 EGFR pathway activation is also involved in tumor growth and 
survival. Stimulation by HER1 ligands has been demonstrated in vitro by inhibition of 
ovarian tumor cell growth upon HER1 activation blockade
31
 and in vivo by the 
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ablation of ovarian tumor cell xenograft growth when mice are depleted of EGF.
32
 
HER1 may support cancer cell invasion and migration through the regulation of cell 
adhesion proteins.
33, 34
 When HER1 expression was decreased in OVCAR-8 ovarian 
cancer cells, a selective decrease in cell clustering and adhesion to laminin-1 was 
observed. Cells with inhibited HER1 expression also lost MMP-9 activity and had 
impaired migratory capacity.
33
 Depleted HER1 expression resulted in decreased E-
cadherin expression by tumor cells.
34
 Furthermore, overexpression of HER1 by tumor 
cells is associated with resistance to hormone therapies, chemotherapy and 
radiotherapy.
29, 35-37
 One proposed mechanism for this tumor cell escape is that HER1 
activation leads to the up-regulation of the apoptosis inhibitor protein, survivin, which 
is found at high levels in many tumor types.
35
 
Since members of the EGFR family are overexpressed on many solid tumors, 
including ovarian carcinomas, and expression is associated with poorer patient 
outcomes,
37
 they present promising targets for therapy. Specifically, HER1 is 
expressed in 25–50% of ovarian cancers21 and HER2 expression is thought to range 
from 5 to 66%, but expression levels are low in peripheral normal tissues. 
PDGFRα 
Platelet-derived growth factor receptor-α (PDGFRα) is a 170 kDa member of the 
class III receptor tyrosine kinase family. Upon binding of platelet-derived growth 
factor (PDGF), receptor dimerization occurs, leading to downstream events including 
stimulation of tumor cell growth and inhibition of apoptosis, and regulation of stroma 
and angiogenesis.
38
 
Elevated PDGF and PDGFRα have been detected in ovarian cancer tissue across 
serous, mucinous and endometrioid histologies and different stage of disease.
38-40
 In 
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ovarian cancer cell cultures, an autocrine mechanism of PDGF/PDGFRα-mediated 
tumor cell growth was identified.
41
 Furthermore, associations between prognosis and 
tumor cell PDGFRα expression have also been observed.39, 40 
NaPi2b 
NaPi2b (SLC34A2) is a multi-transmembrane, sodium-dependent phosphate 
transporter (also termed the TAA, MX35). This TAA is expressed in ~90% of ovarian 
cancers; overexpression of NaPi2b was detected in specimens from all histological 
types of EOC, but not mucinous tumors. Expression is restricted in normal tissues, 
making NaPi2b a potential target of immunotherapeutic and diagnostic approaches for 
EOC. In addition, NaPi2b levels tend to be higher in well-differentiated EOC, 
suggesting that expression may be a marker of low grade tumors and better 
prognosis.
42
 
EFNA4 
Ephrin-A4 (EFNA4), a member of the Ephrin (Eph) family of receptors, is a tumor 
antigen that is overexpressed by a number of different tumors, including primarily 
triple negative breast cancers and ovarian cancers. Recently EFNA4 has also been 
identified as a novel tumor-initiating cell (TIC)-associated target.
43
 TICs are a 
subpopulation of tumor cells that drive tumor growth, resistance to treatment, and 
disease recurrence. These characteristics could render Ephrin-A4 a promising target 
for antibody therapies. 
Tumor-promoting molecules 
Tumor promoting molecules are secreted by cancer cells in order to support tumor 
growth and suppress or subvert anti-tumoral immune responses (Figure 1). These 
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have also become targets for antibody therapeutic strategies. Two key examples are 
discussed here. 
VEGF 
Vascular endothelial growth factor (VEGF) is a pro-angiogenic cytokine that binds 
specific tyrosine kinase receptors (VEGFRs). This leads to the activation of 
downstream pathways that enhance endothelial cell proliferation and survival, 
increase migration and invasion of endothelial cells, increase permeability of existing 
vessels, and enhance homing of vascular precursor cells from the bone marrow. All of 
these aid the formation of new blood vessels; a critical part of the survival, 
proliferation, invasion and metastasis of cancer cells.
44
 VEGF can also have autocrine 
effects on tumor cells, directly influencing their survival, migration and invasion, and 
immune suppression.
44
 VEGF and VEGFR, both expressed in EOC, form an 
autocrine loop that protects EOC cells from apoptosis in anchorage free growth 
conditions (anoikis). In vitro studies, using a number of ovarian carcinoma cell lines, 
have demonstrated that blockade of VEGF-VEGFR engagement results in an 
abolishment of receptor auto-phosphorylation and subsequent increases in apoptosis 
of single-cell tumor cultures.
45
 These conditions reflect those of tumor cells in ascitic 
fluid, implying a role for VEGF in ascites development. 
Furthermore, secretion of VEGF by tumor cells is thought to create an 
immunosuppressive microenvironment, where maturation of dendritic cells is ablated, 
and T cell responses are inhibited.
46
 VEGF may also influence homing of bone 
marrow-derived hematopoietic progenitors to ‘prepare’ an organ for metastasis.44 In 
mice, VEGF mediates the homing of VEGFR-positive hematopoietic precursor cells 
to form clusters at tumor-specific pre-metastatic sites before the migration of tumor 
cells.
47
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In ovarian cancer, VEGF overexpression correlates with increased microvascular 
density, advanced stage of disease, disease recurrence and decreased survival.
48
 
VEGF serum levels also correlate with advanced disease, poorly-differentiated 
ovarian cancer, the presence of ascites and metastases, and poor patient survival.
49, 50
 
Therefore, it is suggested that VEGF is associated with more aggressive clinical 
behavior in ovarian cancer, and measurement of VEGF in the serum is a proposed 
prognostic biomarker in all stages of ovarian carcinoma.
50, 51
 
IL-6 
IL-6 is a 20 kDa cytokine that is involved in normal follicle development in the 
ovary.
52
 However, elevated IL-6 concentrations have been measured in the serum and 
ascitic fluid of patients with ovarian cancer, and are thought to correlate with volume 
of disease. Furthermore, high serum levels of IL-6 correlate with shorter survival and 
are associated with resistance to chemotherapy.
53, 54
 
Elevated IL-6 may support tumor growth by a number of mechanisms. Although this 
cytokine does not appear to directly promote tumor cell proliferation, it may influence 
the migration and invasion of ovarian cancer cells.
52, 54-56
 When NOM1 and SKOV 
ovarian cancer cells were cultured with IL-6, they showed enhanced chemotactic and 
chemokinetic activity, as well as increased invasiveness.
56
 Invasion of tumor cells is 
often mediated by the action of extracellular matrix (ECM)-degrading proteinases, 
such as metalloproteinases. Incubation with IL-6 blocking antibodies resulted in a 
decrease in the secretion of MMP-9 and MMP-2 by SKOV3 cells in vitro, suggesting 
that IL-6 acts in an autocrine manner on ovarian carcinoma cells to up-regulate 
tumorigenic mediators.
52
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Angiogenesis is also enhanced by IL-6. Endothelial cells in both normal ovary and 
carcinoma specimens have been shown to express functional IL-6 receptors, and thus 
IL-6 secreted by ovarian carcinoma cells is thought to act on the microvascular 
endothelium, to trigger a significant angiogenic response. IL-6 enhanced endothelial 
cell migration in vitro and the degree of angiogenesis in BALB/c mice; however there 
is mixed evidence for whether this process is dependent on IL-6-mediated VEGF up-
regulation.
57
 
IL-6 acts through its hexameric receptor, which contains the common cytokine 
receptor signal-transducing subunit, gp130. When IL-6 binds, it triggers signal 
transduction pathways such as JAK/STAT, Ras/MEK/Erk and PI3K/Akt.
58, 59
 These 
pathways have been implicated in the chemo-resistance of ovarian cancer.
60
 
Taken together, IL-6 has a multi-faceted role in the progression of ovarian cancer, and 
is thus considered to be a potential target for therapy. 
MIF 
Macrophage migration-inhibitory factor (MIF) is a cytokine secreted by granulosa 
cells that is found in follicular fluids of normal ovarian tissue, but it has critical roles 
in malignancy, e.g., increasing angiogenesis and tumor cell migration, suppressing 
p53 activity and activating cyclin D1 and E2F transcription factors. MIF is also 
involved in tumor immune escape: MIF has been shown to down-regulate natural 
killer group 2D receptor (NKG2D), an activating receptor on NK cells and a co-
stimulatory receptor on CD8+ T cells, leading to inhibition of anti-tumoral NK and 
CD8+ T cell cytotoxicity.
61
 
In ovarian cancer tissue, MIF is strongly overexpressed and significantly higher levels 
of MIF mRNA have been measured in ovarian carcinoma tissue compared to normal 
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ovarian tissue. Furthermore, elevated MIF protein levels were detected in ascitic 
fluids from ovarian cancer patients compared to non-malignant ascites and MIF 
expression levels were significantly higher in patients who had developed ascites 
compared to those that had not.
61
 Elevated MIF is also detectable in the serum of 
ovarian carcinoma patients.
62
 Therefore, it has been suggested that MIF may be 
associated with poor prognosis in ovarian cancer, and may be a promising target for 
ovarian cancer therapy. 
Immune checkpoint molecules 
A number of molecules or receptors that are expressed by immune cells have roles in 
either suppressing or activating their functions (Figure 1). By specifically targeting 
these checkpoint molecules, novel therapies aim to upregulate anti-tumor immune 
responses, down-regulate pro-tumor functions or depress regulator pathways utilized 
by tumor cells to subvert anti-tumor responses. 
Natural immune responses have been observed in ovarian cancer. Infiltration of 
immune cells into ovarian tumors was first observed over 30 years ago, and since then 
an association between T cell infiltration and improved survival in ovarian cancer has 
been established.
3, 63-66
 However, ovarian tumor cells take advantage of a number of 
mechanisms to evade or suppress this anti-tumor immunity. Targeting checkpoint 
molecules has shown clinical benefits in other solid tumors such as melanoma and 
some types of lung carcinomas, prompting studies to test this strategy in ovarian 
cancer. 
PD-1 and PD-L1 
The programmed cell death 1 (PD-1) co-inhibitory receptor is expressed on activated 
T cells, and binding of its ligands, PD-L1 and PD-L2, regulates T cell proliferation 
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and immune repsonses.
21
 Ovarian cells are thought to evade anti-tumor immune 
responses by expressing PD-L1, and thus suppressing T cell activation.
67
 In fact, an 
inverse correlation has been observed between PD-L1 expression by tumor cells and 
the number of intra-epithelial CD8+ T lymphocytes in ovarian patient specimens, and 
high PD-L1 expression by ovarian carcinoma cells is associated with poor prognosis. 
Therefore, blockade of this receptor/ligand interaction is thought to be a promising 
therapeutic avenue, which may release the immune blockade to improve anti-tumor 
immunity. In contrast, there is little evidence to-date to support raised PD-L2 
expression in ovarian tumors, with weak or no expression of PD-L2 detected in the 
same cohort of ovarian cancer patient tissues.
68
 
CTLA-4 
A similar immunoregulatory target, CTLA-4 is a CD28:B7 immunoglobulin 
superfamily ligand expressed on activated lymphocytes. CD28 signals are known to 
stimulate T cell activation and survival, whereas the T cell-APC interaction via 
CTLA-4 inhibits T cell responses, and can lead to T cell arrest and inhibition of 
effector functions.
69
 Although the activity of CTLA-4 as part of immune evasion in 
ovarian cancer progression is unclear, therapeutic approaches to prevent its 
immunosuppressive activity may be beneficial and are being explored. 
NKG2A 
NKG2A is an inhibitory receptor that controls both innate immunity (via NK cells) as 
well as adaptive immunity (via cytotoxic T cells). Binding of NKG2A to its ligand, 
HLA-E, which is expressed on tumor cells, results in inhibition of NK and cytotoxic 
T cells, and thus tumor cells are able to escape destruction by NKG2A+ immune 
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cells. Ovarian cancer is a suitable indication for an NKG2A receptor inhibitor, since 
HLA-E is upregulated in ∼80% of tumors70 and appears to be prognostic.71 
DLL4 
Delta-like ligand 4 (DLL4), is an activatory ligand of the Notch signaling pathway, 
which is an intracellular signaling system that plays a critical role in cell survival, as 
well as in embryonic development, tissue repair, hematopoiesis, and the maintenance 
of endothelial and gut epithelial stem cell homeostasis.
72
 Alterations in the Notch 
pathway can therefore result in the development of malignancies. DLL4 is expressed 
at sites of angiogenesis, and is the specific ligand of this pathway in endothelial cells. 
Therefore, DLL4 blockade can result in both ineffective angiogenesis and inhibition 
of tumor growth.
73
 
Monoclonal antibodies for the treatment of ovarian cancer 
Monoclonal antibodies have been developed as vaccines and to target tumor-
associated antigens, tumor-promoting molecules and immune checkpoint molecules. 
Examples of such agents in ovarian cancer are detailed below. Agents that have 
reached Phase 3 clinical trials are summarized in Table 1. Agents approved for 
ovarian cancer treatment by the US Food and Drug Administration (FDA), European 
Medicines Agency (EMA) and UK National Institute for Health and Care Excellence 
(NICE) are summarized in Table 2. 
Monoclonal antibody vaccinations 
Abagovomab 
Abagovomab is a murine monoclonal anti-idiotypic antibody that mimics parts of 
CA125. It is designed to act as an active immunogen aimed at breaking immune 
tolerance to the antigen. A Phase 1 study to evaluate the safety and efficacy of 
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abagovomab in patients with recurrent EOC, individuals with detectable anti-CA125 
antibodies demonstrated prolonged survival in contrast to patients who did not show a 
positive immune response to the vaccination. In a Phase 1b/2 trial, 68% of patients 
developed a specific anti-idiotypic antibody response, and cytotoxicity against 
CA125-positive cancer cells was detected in 27% of patients. Moreover a correlation 
between the detection of anti-anti-idiotypic antibodies (Ab3) and survival time was 
observed.
74
 
Long-term efficacy of abagovomab was evaluated in a Phase 3 study (NCT00418574) 
in ovarian cancer patients who were in complete clinical remission after primary 
surgery and platinum-based chemotherapy. Monthly maintenance injections of 
abagovomab were considered to be safe and induced a robust immune response; 
however, treatment did not prolong PFS or OS.
75
 
Oregovomab 
The murine, anti-CA125 IgG1 antibody, oregovomab, readily binds antigen-
presenting cells (APCs) when complexed with CA125, leading to the production of 
anti-CA125 antibodies, and subsequent B and T cell immune responses.
76
 Clinical 
benefit of this antibody was first observed when used as a technetium-99m-labelled 
radiodiagnostic, and it has been evaluated in a number of Phase 2 and 3 trials. 
In patients with recurrent ovarian carcinoma, oregovomab was well-tolerated, and 
both human anti-mouse antibody (HAMA) and anti-idotype antibody immune 
responses were measured.
77, 78
 Increases in T cell immune responses to CA125, 
autologous tumor and oregovomab were measured in 39%, 63% and 50%, 
respectively, of patients undergoing continued oregovomab and chemotherapy 
treatment.
77
 Patients who mounted immune responses to CA125 or autologous tumor 
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demonstrated significantly improved survival compared to those who did not. 
However, oregovomab monotherapy did not induce such significant clinical outcomes 
in Phase 2 studies in patients following initial first-line surgical and chemotherapy 
treatment. A subpopulation of patients with optimal surgical outcomes appeared to 
demonstrate a possible clinical response to oregovomab; however, these results were 
not repeated in a larger multi-center Phase 3 placebo-controlled trial.
79
 This may be 
due to the significant reduction in circulating CA125 in these post-surgery patients, 
resulting in a relative depression of immune response augmented by oregovomab. 
Given that the most promising outcomes were observed in patients undergoing 
concomitant chemotherapy,
77
 current clinical trials aim to evaluate oregovomab in 
combination with carboplatin and paclitaxel (NCT01616303). Oregovomab was 
granted US and EU orphan designations for treatment of ovarian cancer. 
HMFG1 
HMFG1 is a murine monoclonal IgG1 antibody that recognizes a specific epitope 
(PDTR) on human MUC1. The first Phase 1 clinical study in patients with EOC, who 
had undergone at least one regimen of platinum-based therapy, demonstrated the 
safety and tolerability of repeated intradermal injections of HMFG1. Furthermore, 
anti-idiotypic antibodies were detected in all patients after three vaccinations.
80
 A 
large Phase 3 trial in patients with EOC who had undergone a surgically defined 
complete remission of the disease, was then carried out to compare yttrium-90 labeled 
murine HMFG1 (
90
Y-muHMFG1), plus standard therapy, with standard therapy 
alone. However, no difference in time to relapse was detected between the two arms 
of the study, and a single injection of 
90
Y-muHMFG1 did not improve OS.
81
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Monoclonal antibodies targeting tumor-associated antigens 
PankoMab-GEX 
PankoMab-GEX is a glycoengineered humanized IgG1 mAb specifically targeting the 
PDTRP epitope of MUC1. The optimized glycosylation of PankoMab-GEX leads to 
enhanced antibody-dependent cell-mediated cytotoxicity and phagocytosis 
(ADCC/ADCP).
82
 In a Phase 1 study (NCT01222624) in patients with advanced 
MUC1-expressing solid tumors, PankoMab-GEX was well tolerated; no maximum 
tolerated dose (MTD) was reached and AEs were mainly mild to moderate infusion-
related reactions. Clinical benefit was observed in 47% of patients, including 1 
complete response (CR) in a patient with ovarian carcinoma, and confirmed stable 
disease (SD) in 19 patients.
82
 There is now an ongoing placebo-controlled Phase 2 
study (NCT01899599) of PankoMab-GEX as maintenance therapy in advanced ovarian, 
fallopian tube or primary peritoneal cancer. 
Catumaxomab 
Catumaxomab is a bispecific trifunctional antibody (trAb) specific to both EpCAM 
and CD3, which is expressed on T cells. The unique hybrid Fc portion of the antibody 
is composed of mouse IgG2a and rat IgG2b and selectively binds type I, IIa and III 
human Fcγ receptors expressed on accessory immune cells such as macrophages, NK 
cells and dendritic cells,
83
 leading to ADCC and ADCP, and activation of T-cell 
mediated tumor cell cytotoxicity.
84
 
In a Phase 1/2 study of catumaxomab in ovarian cancer patients with ascites 
containing EpCAM-positive tumor cells, significant ascites reduction was observed 
and minimal adverse events (AEs) occurred.
83
 A subsequent Phase 2/3 trial 
comparing paracentesis plus catumaxomab with paracentesis alone showed that 
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 04
:07
 09
 A
ug
us
t 2
01
6 
 21 
 
addition of catumaxomab significantly prolonged puncture-free survival and time to 
next paracentesis. Furthermore, patients given catumaxomab suffered fewer 
symptoms from ascites and had a positive trend in OS.
85
 Catumaxomab has EMA and 
NICE approval for use in EpCAM-positive ascites treatment (see Table 2). 
chMOv18 IgG 
chMOv18 IgG is a human chimeric IgG1 antibody specific for FRα, cloned from a 
murine MOv18 IgG antibody that was generated by immunization of mice with a 
surgical specimen of ovarian cancer.
86
 Following studies showing effective tumor 
uptake and anti-tumor efficacy of radiolabeled murine MOv18 IgG,
87
 radiolabeled 
chMOv18 IgG was shown to localize well into the tumor tissue of ovarian cancer 
patients.
88
 Results of a Phase 1 trial, in which chMOv18 IgG given intravenously 
(i.v.) at increasing doses, indicated that the antibody was safe with no significant 
hematological or biochemical changes.
89
 
The route of administration for radiolabeled chMOv18 IgG was evaluated in two 
studies comparing i.v administration with locoregional delivery via intraperitoneal 
(i.p.) administration.
90, 91
 Radiolabeled chMOv18 IgG given either i.p or i.v. was 
considered to give no normal organ toxicity, with no AEs observed. One study 
suggested that that better accumulation of antibody occurred after locoregional i.p 
administration, compared to i.v.,
90
 but the other study did not measure any advantage. 
Use of the i.p route of administration was recommended with respect to bone marrow 
toxicity, as the area under the blood activity vs. time curve (AUC) was significantly 
lower for the i.p. route.
91
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Farletuzumab 
Farletuzumab (MORab003) is a humanized IgG1 antibody specific for FRα. 
Following in vitro studies showing a number of mechanisms of anti-tumor activity,
92, 
93
 a Phase 1 study, in patients with platinum-resistant EOC was carried out to 
establish the MTD.
94
 The safety of farletuzumab in combination with carboplatin and 
pegylated liposomal doxorubicin in patients with platinum-sensitive EOC was then 
demonstrated in a Phase 1b study.
95
 
Promising overall response rates were observed in a Phase 2 study in patients with 
platinum-sensitive ovarian cancer given farletuzumab/carboplatin/taxane combination 
therapy, followed by farletuzumab maintenance therapy. Furthermore, farletuzumab 
did not lead to additive toxicity when combined with chemotherapy.
96
 Subsequently, a 
Phase 3 trial was carried out in platinum-sensitive patients with recurrent ovarian 
cancer compared the carboplatin/taxane treatment alone with the addition of 
farletuzumab. Here, improved PFS was observed in patients with lower CA125.
97
 A 
second Phase 3 study in patients with platinum-resistant ovarian cancer compared 
paclitaxel alone, or in combination with farletuzumab (NCT00738699); however this 
trial was discontinued when the pre-specified criteria for continuation were not met. 
The manufacturer of farletuzumab has since announced the development of a 
diagnostic assay to identify patients with high FRα expression, suggesting that 
farletuzumab trials in the future may stratify patients according to tumor target 
expression.
98
 The suggestion that farletuzumab may be most beneficial in patients 
with low CA125 serum levels is being addressed in a Phase 2 study comparing 
farletuzumab, combined with carboplatin and paclitaxel, or with carboplatin and 
pegylated liposomal doxorubicin (NCT02289950). 
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Amatuximab 
Amatuximab (MORAb-009) is a high-affinity chimeric IgG1 mAb targeting 
mesothelin. Following promising preclinical studies,
99
 a Phase 1 study of amatuximab 
in 24 patients with treatment-refractory, mesothelin-expressing solid tumors was 
initiated. In this study, amatuximab was well tolerated, an MTD of 200 mg/ml
 
was 
determined and 11 patients experienced SD, with no observed objective responses. 
The most common AE was drug hypersensitivity consisting of infusion 
reactions/cytokine release syndrome and allergic reactions.
100
 To date, no Phase 2 
trials in ovarian cancer have been planned for this antibody. 
Cetuximab 
Cetuximab is a chimeric IgG1 antibody specific for the extracellular domain of EGFR 
(i.e., HER1) that is approved for use in colorectal and head and neck cancers. Upon 
binding, the antibody prevents signaling via EGFR, and accelerates internalization of 
the receptor.
101
 Cetuximab demonstrated anti-tumor activity and augmentation of the 
efficacy of chemotherapies such as cisplatin, doxorubicin, paclitaxel, and topotecan 
both in vitro studies and in human xenograft animal models.
102
 In a Phase 2 trial of 
cetuximab as a single agent in patients with persistent/recurrent ovarian cancer, 
minimal clinical benefit was observed, with 9 patients achieving SD and only 1 
patient demonstrating a partial response (PR).
103
 Furthermore, in a Phase 2 study of 
cetuximab, combined with paclitaxel and carboplatin, in patients with stage III/IV 
ovarian cancer, this combination therapy was adequately tolerated, but did not 
demonstrate prolonged PFS compared to historical data.
104
 More promising results 
were observed in another Phase 2 study, where cetuximab was combined with 
carboplatin in platinum-sensitive ovarian cancer patients. Here 9 of 29 patients had an 
objective response and 8 patients had SD. As previously observed, cetuximab therapy 
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was associated with an acneiform rash in the majority of patients, and occasional 
serious hypersensitivity reactions were observed.
105
 
Although meaningful efficacy data is lacking for the use of cetuximab in ovarian 
cancer, future developments may include the use of pharmacogenetic data (such as K-
RAS mutation status) to select appropriate patients for treatment, as has been carried 
out for colorectal cancer, or cetuximab may be used in combination VEGF inhibitors 
such as bevacizumab.
103, 104
 
Panitumumab 
Panitumumab is a human recombinant IgG2 mAb approved for use in metastatic 
colorectal cancer.
106
 It binds to the extracellular domain of EGFR/HER1, preventing 
its activation.
107
 In a Phase 2 study, platinum-resistant, K-RAS wild-type, EOC 
patients were given panitumumab in combination with pegylated liposomal 
doxorubicin. Overall response as determined by CA125 levels was observed in 18.6% 
of the intent-to-treat population. Using RECIST evaluation, 9.3% of patients had a 
PR, 18.6% had SD and 39.5% progressed on treatment. The most common treatment-
related grade 3 toxicities were skin toxicity, fatigue and vomiting, and skin toxicities 
were the major reason for dose reductions. Overall, although a moderate response rate 
was observed, the occurrence of skin toxicities was considered to have a substantial 
effect on the quality-of-life of patients.
108
 The K-RAS mutation status of patients may 
be a useful molecular marker for selection of patients to treat with panitumumab. 
Panitumumab in combination with everolimus and bevacizumab was also evaluated in 
a Phase 1 study in patients with advanced solid tumors.
107
 Three of the 32 subjects 
had ovarian cancer, and these individuals showed prolonged disease control ranging 
from 11 to >40 months. The recommended combination dose regimen showed 
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acceptable safety and tolerability and moderate clinical activity, particularly in 
gynecological cancers.
107
 More recently, a Phase 2 trial of panitumumab combined 
with gemcitabine in patients with relapsed ovarian cancer was terminated because 
newer technologies are available and the study had poor accrual (NCT01296035). 
Matuzumab 
Matuzumab (EMD72000) is a humanized IgG1 mAb that binds to EGFR/HER1 at the 
ligand-binding region. It is thought that matuzumab acts by inhibiting EGFR binding 
and signaling, and by triggering ADCC against EGFR-expressing tumor cells.
109
 
Results of a Phase 1 studies in colon cancer patients showed matuzumab was well 
tolerated, with the predominant toxicities being those of the skin.
110
 A Phase 2 trial in 
patients with recurrent, EGFR-positive ovarian cancer demonstrated that the therapy 
was reasonably well tolerated, although no formal responses of matuzumab efficacy 
were observed.
109
 
Trastuzumab 
Trastuzumab is a humanized IgG1 antibody that binds to the extracellular domain IV 
of HER2, preventing activation of the intracellular tyrosine kinase, and thus inhibiting 
proliferation of cells overexpressing HER2.
111
 It is approved for breast cancer and 
adenocarcinoma of the stomach. On the basis of the observed safety of trastuzumab in 
breast cancer, a single-arm Phase 2 trial of trastuzumab was carried out in persistent 
or recurrent ovarian cancer patients selected on the basis of high levels of HER2 
tumor expression. Only a 7.3% response rate and 39% disease stabilization rate was 
observed in these patients. However, several patients that responded or showed SD 
continued to receive trastuzumab therapy for more than 1 year, demonstrating the 
overall tolerability of treatment; reported drug related toxicities tended to be mild and 
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not dose-limiting. Furthermore, data from this study suggested that there was no 
correlation between the level of HER2 expression and response to trastuzumab 
treatment.
111
 Another Phase 2 study of trastuzumab combined with a carboplatin-
paclitaxel regimen was also initiated in patients with ovarian cancer that had 
previously relapsed within 6 months of carboplatin-paclitaxel treatment and had high 
levels of tumor HER2 expression. This trial has since been terminated with no reason 
reported (NCT00189579). 
A Phase 3 trial (NCT00011986) of trastuzumab in triplet or doublet treatment 
combinations with paclitaxel and carboplatin in patients with EOC has been reported 
as complete, although results have not yet been published. A number of other Phase 1 
studies evaluating trastuzumab in combined with interleukin-12 have also been 
carried out, with results yet to be reported (NCT00028535 and NCT00004074). 
Pertuzumab 
Pertuzumab (rhuMAb 2C4) is an IgG1 humanized mAb that binds to the extracellular 
domain II of HER2, preventing hetero-dimerization with HER1 or HER3. It is 
approved for use in breast cancer treatment,
112
 but has shown efficacy against ovarian 
cancer cells in vitro.
113-116
 In the Phase 1 study in patients with advanced solid tumors, 
pertuzumab was well tolerated, and two of the 21 patients, including one with ovarian 
cancer, achieved a PR.
117
 In a Phase 2 trial, pertuzumab alone was evaluated in 
platinum-resistant ovarian cancer. Overall, 14.5% of participants were considered to 
have achieved any clinical benefit.
118
 In a larger Phase 2 trial, pertuzumab combined 
with gemcitabine was compared to gemcitabine plus placebo in platinum-resistant 
patients. The objective response rate was 13.8% in patients receiving the combination, 
compared to 4.6% in those receiving gemcitabine and placebo. This increased benefit 
of pertuzumab was shown to occur more in patients with lower HER3 mRNA 
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expression, whereas patients with high HER3 tumor expression were less likely to 
benefit from pertuzumab addition to treatment. In this study, an increased incidence 
of grade 3 and 4 neutropenia, thrombocytopenia, back pain and diarrhea were 
observed in the combination arm.
115
 The efficacy of pertuzumab was also evaluated in 
a Phase 2 trial in combination with carboplatin and paclitaxel or gemcitabine in 
platinum-sensitive patients; however no significant differences in PFS or other 
secondary endpoints were observed between the cohorts.
119
 
Although HER2 expression by ovarian cancer and breast cancer cells is comparable, 
efficacy of pertuzumab in ovarian cancer is not equivalent to that seen in treating 
breast cancer.
112
 This may be dependent on HER3 expression
115
 or HER2 
activation.
114
 Therefore, future pertuzumab studies are likely to include stratification 
of patients using such biomarkers. There is an ongoing Phase 3 study combining 
pertuzumab and standard chemotherapy in platinum-resistant ovarian cancers with 
low HER3 mRNA expression (NCT01684878), and another Phase 2 trial evaluating 
HER2 activation on pertuzumab efficacy in advanced ovarian cancer has just been 
completed, with results yet to be reported (NCT00058552). 
Seribantumab 
Seribantumab (MM-121, SAR256212) is a human HER3-targeting IgG2 mAb that 
prevents the dimerization of HER2 and HER3 and inactivates downstream signaling. 
120
 This antibody has recently been evaluated in combination with paclitaxel in a 
randomized Phase 2 study of platinum resistant advanced ovarian and fallopian tube 
cancer (NCT01447706). Most reported AEs were mild to moderate; however PFS 
was not prolonged by combination of seribantumab with paclitaxel.
121
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Olaratumab 
Olaratumab (IMC-3G3), a human IgG1 mAb that selectively binds PDGFRα, 
prevents ligand binding
122
 and significantly enhances the efficacy of chemotherapy 
against ovarian tumor cells in vitro and in vivo.
123
 In a Phase 1 study in patients with 
solid tumors olaratumab was well tolerated and no DLTS were observed so the MTD 
was not identified. No CR or PR was measured, but SD was measured in 12 of the 19 
evaluable patients and RP2Ds of 16 mg/kg weekly and 20 mg/kg biweekly were 
determined. 
122
 A Phase 2 study (NCT00913835) evaluating the efficacy of PLD, with 
or without olaratumab, in platinum-refractory or resistant advanced ovarian cancer 
has been conducted and results are awaited. 
Monoclonal antibodies targeting tumor-promoting molecules 
Bevacizumab 
Bevacizumab, a recombinant humanized monoclonal IgG1 antibody specific to all 
biologically active forms of VEGF-A, has demonstrated anti-angiogenic activity and 
inhibition of ovarian cancer progression in in vitro studies and animal models.
124
 In a 
Phase 2 study in patients with recurrent EOC and primary peritoneal cancer (PPC), 
3% and 18% of patients showed CR and PR, respectively, and 40% of patients 
showed at least 6 months PFS following treatment.
125
 
A number of Phase 3 trials of bevacizumab have been completed. In patients with 
EOC, PPC and fallopian tube cancer, paclitaxel/carboplatin treatment combined with 
placebo was compared to concurrent bevacizumab, and concurrent plus maintenance 
bevacizumab. Although concurrent bevacizumab treatment showed no improvement 
in PFS compared to the chemotherapy arm, patients who also received concurrent 
plus maintenance bevacizumab had an increased PFS of 3.8 months. However, no 
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difference in OS was observed. Bevacizumab treatment was well tolerated, with the 
major AEs attributed to chemotherapy.
126
 In another Phase 3 trial, patients with EOC 
were treated with carboplatin and paclitaxel alone or in combination with concurrent 
bevacizumab. Here, improved PFS was observed in those receiving chemotherapy 
combined with bevacizumab.
127
 The efficacy of bevacizumab in combination with 
chemotherapy has also been studied in a Phase 3 trial in patients with platinum-
resistant ovarian cancer. Patients were treated with paclitaxel, pegylated liposomal 
doxorubicin (PLD) or topotecan alone, or combined with bevacizumab. Those 
receiving bevacizumab in combination with chemotherapy showed significantly 
improved PFS.
128
 The observed improvements in these studies may not only be due to 
the anti-angiogenic effect of bevacizumab, but may also be attributed to 
bevacizumab–related normalization of tumor vasculature, which may lead to 
enhanced delivery of chemotherapeutic drugs. Bevacizumab is approved for ovarian 
cancer treatment by the FDA, EMA and NICE (see Table 2). 
Volociximab 
Volociximab is a first-in-class chimeric IgG4 mAb that targets human 51 integrin 
with high affinity. Preclinical studies of this antibody, which showed inhibition of 
VEGF- and bFGF-induced neovascularization, associated reduction in tumor burden, 
ascites and number of metastases, and increased survival in animal models of ovarian 
cancer,
129
 were followed by a number of clinical trials. In a Phase 1 study, no DLTs 
were observed and dose reduction was not required. Of the 20 patients evaluable for 
efficacy, 1 patient with renal cell carcinoma had a minor response and 5 others had 
durable SD. No CRs or PRs were observed.
130
 Subsequently, a multicenter Phase 2 
single-arm, two-stage study in platinum-resistant advanced EOC or primary 
peritoneal cancer was carried out. Of the 14 patients evaluable for efficacy, 1 had SD 
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at 8 weeks, but the remaining 13 patients all demonstrated PD. This lack of efficacy 
may have been caused by the chemotherapy-resistant study population. In addition, 
75% of patients experienced AEs, primarily headache and fatigue.
131
 In a second 
Phase 2 study, patients with EOC were stratified by platinum sensitivity and treated 
with PLD or volociximab alone, or the combination.
132
 AEs and response rates were 
similar across treatment groups.
132
 
Siltuximab 
Siltuximab (CNTO 328, cCLB8) is a chimeric mAb that binds to IL-6, neutralizing its 
effects in a number of human malignancies including ovarian cancer. Following in 
vitro analyses showing that the intensity of IL-6 immunohistochemistry (IHC) 
staining of ovarian cancer tissues was associated with poor patient prognosis, and that 
siltuximab had tumor growth efficacy, a single arm, Phase 2 study of siltuximab in 
patients with recurrent, platinum-resistant ovarian cancer was conducted. Although 
the response rate to siltuximab, the primary endpoint of the study, was modest, 
prolonged periods of disease stabilization were observed. Median OS was similar to 
that of large Phase 2 trials of conventional chemotherapy in platinum-resistant ovarian 
cancer.
133
 Plasma cytokine/chemokine levels were also almost unchanged following 
three siltuximab infusions; however, patients who received at least six months of 
infusions showed lower levels of IL-6-regulated chemokines, CCL2 and CXCL12, 
and the angiogenic molecule VEGF. Efficacy of siltuximab was also evaluated in a 
Phase 1/2 study in patients with advanced solid tumors, including EOC. This study 
was successful in demonstrating that siltuximab monotherapy is well tolerated, but it 
did not demonstrate clinical activity.
134
 No additional studies have been initiated in 
ovarian cancer. 
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Imalumab 
Imalumab (Bax69) is a human IgG1 mAb that targets oxidized MIF (oxMIF) to 
reduce tumorigenesis. Interim reports of a Phase 1 study in solid tumors 
(NCT01765790), report that imalumab was well tolerated and no MTD had been 
reached. SD was measured in 7 heavily pretreated patients and a recommended Phase 
2 dose (RP2D) of weekly 10 mg/kg i.v. was determined.
135
 A Phase 1/2a study of 
imalumab is now recruiting patients with ovarian carcinoma and recurrent malignant 
ascites (NCT02540356). In this study, imalumab monotherapy will be administered 
i.p. (study single-route arm) and compared to i.v. followed by i.p. infusions (double-
route arm). 
Monoclonal antibodies specific for immune targets 
Nivolumab 
Nivolumab is a human anti-PD-1 IgG4 mAb. A Phase 1 study in patients with 
advanced tumors demonstrated clinical responses to nivolumab. The greatest rate of 
response was observed in melanoma patients; of the 17 ovarian cancer patients 
treated, 6% had a PR and 18% had SD.
136
 In a Phase 2 trial in platinum-resistant 
ovarian cancer the overall response rate to nivolumab was 15%, and the disease 
control rate was 45%. The median OS for the cohort was 20 months.
137
 Strategies for 
patient stratification are still unclear as no significant correlation between clinical 
response and patient tissue PD-L1 expression was identified.
137
 
Pembrolizumab 
Recently, interim results were presented from a Phase 1b study of pembrolizumab, a 
humanized anti-PD-1 IgG4 mAb. Of the 26 patients with PD-L1-expressing advanced 
ovarian cancer who were treated with pembrolizumab, 1 patient had a CR, 2 achieved 
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PR, and 6 had SD, resulting in a disease control rate of 34.6%. 
138
 
BMS-936559 
A human anti-PD-L1 IgG4 mAb, BMS-936559, has been evaluated in a Phase 1 study 
that included patients with ovarian cancer. In this study, 6% of patients receiving the 
MTD of 10 mg/kg achieved PR and 18% had SD lasting more than 24 weeks.
139
 
Avelumab 
A human IgG1 mAb targeting PD-L1, avelumab (also known as MSB0010718C) is 
unlike other PD-L1 targeting mAbs as it is able to mediate ADCC of tumor cells (due 
to its functional IgG1 Fc region). In a Phase 1 study in patients with refractory 
cancers, including ovarian carcinoma, significant inhibition of the PD-L1 receptor on 
peripheral blood lymphocytes (PBLs) was measured following avelumab treatment. 
To-date, the data from this study are still being collected. However, preliminary 
results from an ongoing Phase 1b study in patients with recurrent or refractory ovarian 
cancer (NCT01772004) have shown that 17.4% of patients had a PR and 47.8% had 
SD.
140
 A Phase 3 study to evaluate avelumab alone, compared to avelumab combined 
with PLD, and PLD alone, is now recruiting patients with platinum-resistant or 
refractory ovarian cancer (NCT02580058). 
Ipilimumab 
Ipilimumab, a human IgG1 targeting CTLA-4, was approved by the FDA in 2011 for 
treatment of metastatic or unresectable melanoma. The mAb was well tolerated in a 
Phase 1/2 trial in patients with stage IV ovarian carcinoma, who had previously either 
received chemotherapy or granulocyte-macrophage colony-stimulating factor 
modified irradiated autologous tumor cells (GVAX).
141, 142
 One ovarian cancer patient 
had a significant decrease in serum CA125 levels and tumor regression, and an 
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additional 5 patients showed stabilization of CA125 levels.
142
 Furthermore, the 
therapeutic effects of ipilimumab were associated with anti-NY-ESO-1 antibody 
responses. Tumor regression also correlated with the CD8+/Treg ratio, suggesting that 
other Treg-depleting therapies may be combined with ipilimumab for a synergistic 
effect. Another Phase 2 study (NCT01611558) of ipilimumab monotherapy in patients 
with platinum-sensitive ovarian cancer is ongoing. 
Tremelimumab 
Tremelimumab is a human IgG2 mAb that targets CTLA-4. An ongoing Phase 1/2 
trial (NCT02571725) is evaluating the combination of tremelimumab with the PARP-
inhibitor olaparib in patients with BRCA-deficient recurrent ovarian cancer. Phase 1 
studies (NCT02261220, NCT01975831) of tremelimumab combined a PD-1 inhibitor, 
MEDI4736, in patients with solid tumors including ovarian cancer are also now 
recruiting.
143
 
Monalizumab 
Monalizumab (IPH2201) is a humanized IgG4 mAb that blocks the binding of 
NKG2A to HLA-E, allowing activation of NK and cytotoxic T cell responses. 
IPH2201 may also enhance the cytotoxic potential of other therapeutic antibodies. In 
a Phase 1 dose-escalation study, monalizumab was safe and well-tolerated.
144
 It is 
currently under evaluation in a Phase 1/2 trial (NCT02459301) of platinum-resistant 
or sensitive patients with high grade ovarian cancer. 
Demcizumab 
Demcizumab (OMP-21M18) is a humanized IgG2 mAb targeting DLL4. The Phase 1 
study of demcizumab demonstrated initial single-agent activity, including early 
evidence of durable anti-tumor responses. This study included one patient with an 
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ovarian granulosa cell carcinoma who demonstrated SD as best response, and 
remained on treatment for 17 months.
145
 Overall, therapy was generally well 
tolerated; however, the prolonged exposure to demcizumab, as with the patient with 
ovarian granulosa cell carcinoma, resulted in delayed cardiac toxicity and tumor-
associated bleeding consistent with dysfunctional angiogenesis, necessitating 
termination of the study.
145
 A Phase 1b/2 study (NCT01952249) of demcizumab, plus 
paclitaxel, is now recruiting patients with platinum-resistant ovarian, primary 
peritoneal or fallopian tube cancer. 
Antibody-Drug Conjugates 
An antibody-drug conjugate (ADCs) directs the potent activity of a small molecule 
cytotoxic agent to the appropriate tumor cells by covalently attaching the agent to a 
tumor antigen-specific mAb. Most cytotoxic agents used as payloads in ADCs are 
potent microtubule inhibitors or DNA damaging agents, and do not have a therapeutic 
index when administered as free drugs.
146
 
DMUC4064A 
DMUC4064A is an ADC composed of a CA125-targeting humanized IgG1 
conjugated to an anti-mitotic agent, MMAE. A Phase 1 study (NCT02146313) of 
DMUC4064A in patients with platinum-resistant ovarian cancer or unresectable 
pancreatic cancer is ongoing. 
IMGN853 
IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC composed of a 
humanized FRα-binding antibody attached to a highly potent maytansinoid, DM4, 
that induces cell-cycle arrest and cell death by targeting microtubules.
147
 A Phase 1 
study in patients with EOC or other FR-positive solid tumors, demonstrated 
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encouraging clinical activity in heavily pretreated patients, with a manageable AE 
profile.
148
 Clinical benefit (PR or CR, CA125 response, SD ≥ 6 cycles) was observed 
in 11/44 patients.
149
 In another trial, the RP2D showed clinical benefit in 5/10 
evaluable patients with platinum-resistant EOC. A Phase 1b study of IMGN853 
administered with bevacizumab, carboplatin, or PLD, in patients with FRα-positive 
advanced EOC, primary peritoneal cancer, fallopian tube cancer or endometrial 
cancer is open to recruitment (NCT02606305). Furthermore, a Phase 2 study 
(NCT02631876) is recruiting patients with FRα-positive advanced EOC, primary 
peritoneal cancer or fallopian tube cancer to compare IMGN853 with the 
investigator’s choice of chemotherapy. 
DNIB0600A 
DNIB0600A (lifastuzumab vedotin) is a humanized IgG1 anti-NaPi2b mAb 
conjugated to an anti-mitotic agent, MMAE, that has shown anti-proliferative activity 
in xenograft models.
150
 In a Phase 1 study of DNIB0600A in patients with non-small 
cell lung cancer or platinum-resistant ovarian cancer, archival tumor NaPi2b 
expression was evaluated by IHC.
151
 At the recommended Phase 2 dose, 41% of IHC 
2/3+ patients with ovarian cancer had confirmed PRs. No patient with an IHC score of 
0 showed a clinical response.
151
 DNIB0600A in combination with carboplatin, and 
with or without bevacizumab is now being evaluated in a Phase 1b study 
(NCT01995188) in patients with platinum-sensitive ovarian cancer. A Phase 2 
randomized trial (NCT01991210) of DNIB0600A, in comparison to PLD, in patients 
with platinum-resistant ovarian cancer is also ongoing. 
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PF-06647263 
PF-06647263 is a first-in-class, humanized IgG2 mAb (huE22) specific for EFNA4, 
and linked to calicheamicin, a DNA-damaging cytotoxic agent.
43
 Initial results from a 
Phase 1 study in patients with advanced solid tumors unselected for EFNA-4 
expression show a DLT in only 1 patient, and two patients (1 with ovarian cancer and 
one with triple negative breast cancer) have experienced a PR.
152
 
SC-003 
SC-003 is an ADC composed of a proprietary TAA-specific mAb conjugated to an 
undisclosed cytotoxic agent with unpublished mechanism of action.
153
 A Phase 1 
study (NCT02539719) of SC-003 is now recruiting patients with platinum-resistant, 
refractory ovarian cancer. 
New Directions for Ovarian Cancer Immunotherapy 
IMAB027 
A proportion of advanced stage ovarian cancers express high levels of Claudin 6 
(CLDN6), a carcino-embryonic transmembrane protein that is not found on normal 
adult human tissue. IMAB027 is a mAb that binds to CLDN6. Pre-clinically, this 
antibody was shown to inhibit tumor growth and to kill cancer cells by ADCC and 
complement-dependent cytotoxicity (CDC). A Phase 1/2 trial (NCT02054351) of 
IMAB027 in patients with recurrent advanced ovarian cancer is currently underway. 
Early data suggests that IMAB027 was well tolerated, with no DLTs observed, and 
the MTD was not reached.
154
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MOv18 IgE 
MOv18 IgE is a FRα-specific chimeric IgE antibody engineered from MOv18 
IgG1.
155
 Following trial results of farletuzumab and chMOv18 IgG1, where FRα was 
shown to be a promising target and chMOv18 IgG1 was well tolerated (described 
above), MOv18 IgE was developed to investigate the hypothesis that antibodies 
engineered with Fc regions of the IgE class may offer advantages over their IgG 
counterparts.
156
 MOv18 IgE afforded superior protection compared with its IgG1 
counterpart in a number of in vivo models of ovarian cancer,
157, 158
 and is now 
undergoing evaluation in a Phase 1 clinical study (NCT02546921). 
Conclusion and future perspectives in antibody design 
Improved understanding of the contribution of tumor-associated molecules to ovarian 
cancer growth and spread has helped identify known and novel targets for therapy. 
Alongside novel emerging targets involved in immune regulation, these insights are 
now yielding a range of different treatment approaches involving monoclonal 
antibodies. 
One area likely to receive increasing attention may be antibody engineering strategies 
aimed at enhancing Fc-mediated antibody mechanisms of action and 
bioavailability.
159
 These may include: 1) engineering of antibodies or antibody 
fragments with specificity for more than one target (e.g., bispecific antibodies), with 
the aim of simultaneously recruiting immune effector cells to the tumor target; 2) 
engineering of differentially glycosylated Fc regions in order to enhance antibody 
bioavailability and augment the capacity of antibodies to trigger ADCC; or 3) 
mutational engineering of antibody Fc regions with the aim of improving both ADCC 
and CDC. Beyond antibody engineering techniques, attempts at augmenting Fc-
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mediated responses have been made, by strategies to increase the activation, 
expansion and recruitment of effector cells such as by co-administering the antibody 
with recombinant cytokines. 
All currently approved mAbs are of the IgG isotype
160
 due to favorable 
pharmacokinetic properties and the pioneering experiments by Neuberger and 
colleagues, which demonstrated that IgG, and in particular IgG1, was more effective 
than other antibody isotypes in activating complement and promoting ADCC and 
CDC against tumor cells in vitro. Different IgG antibody subclasses, however, have 
been employed therapeutically, such as IgG1, IgG2 and IgG4, depending on the 
desired role of the Fc-mediated mechanisms of action. The IgG1 Fc region generally 
has the highest affinity of all of the IgG antibody subclasses for Fc receptors (FcRs) 
on immune effector cells, leading to more potent effector functions.
161
 On the other 
hand, IgG4 has weaker affinity for FcRs, which translates into weaker or ineffective 
effector functions. Therefore, IgG4 mAbs are used therapeutically when Fc-mediated 
effector functions are not desirable.
136
 Furthermore, there has been some exploration 
of the use of mAbs of alternate Ig classes such as IgA and IgE in cancer 
immunotherapy, with the aim of enhancing Fc-mediated effector functions at 
anatomic locations where tumors may be located, and through the engagement of 
cognate FcRs on immune effector cells such as FcαRI, FcεRI, and CD23.155-158 
Another area likely to expand will be the identification of effective combinatory 
treatments. Single-agent immunotherapies have produced promising clinical 
responses in ovarian carcinoma and other tumors. However, to achieve the maximal 
anti-tumor immune response, it is likely that combination therapeutic strategies will 
be required. For many tumors, several ‘tumor escape mechanisms’ acting in parallel 
allow tumors to evade detection by the immune system.
162
 The concept behind a 
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combinational immunotherapy strategy is to target tumor escape mechanisms at 
different stages, thereby creating the possibility of synergistic effects between agents 
and potentially benefiting a greater proportion of patients. 
An example of a combination antibody immunotherapy strategy in ovarian cancer 
involves the combination of multiple immune checkpoint blockades. In preclinical 
studies, almost half of the tumor-infiltrating lymphocytes in an in vivo model of 
ovarian carcinoma were positive for both CTLA-4 and PD-1, and demonstrated an 
attenuated capacity to proliferate and produce cytokines.
163
 Treating these mice with 
both anti-PD-1 and anti-CTLA-4 antibodies resulted in reversal of the tumor-
infiltrating lymphocyte dysfunction, and induced tumor regression in 50% of the mice 
compared to 25% with either agent as a monotherapy.
163
 A Phase 1/2 trial evaluating 
nivolumab and the IDO inhibitor INCB24360 in patients with ovarian cancer is 
currently underway (NCT02327078). Since the IDO pathway leads to the expansion 
of Tregs, combining an agent that enhances effector T cell function with an agent that 
restricts immunosuppressive elements such as myeloid-derived suppressor cell 
(MDSC), Tregs, and macrophage subtypes in the tumor microenvironment may be 
more efficacious than either agent as monotherapy. In another study, a dendritic cell-
based autologous whole-tumor lysate vaccine combined with bevacizumab was 
evaluated in patients with ovarian cancer. Four of six patients demonstrated a clinical 
benefit, in addition to an increase in tumor-reactive T cells (as measured by IFN-γ 
secretion).
164
 
Although it is likely that the interest in novel combination immunotherapy studies in 
ovarian cancer will increase, simultaneous application of multiple immunotherapies 
requires careful consideration of: 1) the potential for overlapping toxicities; 2) the 
need to optimize the timing of administration of each agent (sequential vs. 
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concurrent); and 3) the critical issue of patient stratification, e.g., which patients need 
combination strategies and what combinations are best in any given patient. A 
proportion of patients treated with monotherapy demonstrate prolonged responses, 
suggesting that some patients may not need combination immunotherapy. There is an 
urgent need to develop biomarkers to identify such patients to preselect them for each 
monotherapy in order to avoid the toxicities associated with combination 
immunotherapy. If all of these considerations can be managed, it is likely that 
combination immunotherapy, and our improved understanding of mechanisms of 
immune modulation in ovarian carcinoma, may dramatically improve the clinical 
outcomes of ovarian cancer patients. 
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Table 1: Monoclonal antibodies evaluated in Phase 3 studies as treatments for 
ovarian cancer. 
Name Antibody Phase 3 trial design Outcome References 
Monoclonal antibody vaccinations 
Abagovomab Murine anti-
idotypic mAb 
mimicking 
CA125 
EOC in complete 
remission following 
surgery or platinum-based 
chemotherapy; comparing 
abagovomab to placebo. 
Monthly 
maintenance 
injections induced 
immune response. 
No improvement in 
PFS or OS 
measured. 
75 
90
Y-
muHMFG1 
MUC1-
specific 
murine IgG1 
(yttrium-90 
labeled) 
EOC; 
90
Y-muHMFG1 
combined with or 
compared to standard 
therapy. 
No difference in 
time to relapse 
between two arms. 
No improvement in 
OS with 
90
Y-
muHMFG1. 
81 
Monoclonal antibodies targeting tumor-associated antigens
 
Catumaxomab EpCAM and 
CD3 bi-
specific 
(trAb) 
Combined with 
paracentesis in recurrent 
symptomatic malignant 
ascites resistant to 
conventional 
chemotherapy. 
Prolonged 
puncture-free 
survival and time to 
next paracentesis, 
compared to 
paracentesis alone. 
85 
Farletuzumab FRα-specific 
humanized 
IgG1  
Platinum-sensitive 
recurrent OC; comparing 
carboplatin/taxane 
treatment alone and with 
the addition of 
farletuzumab. 
Improved PFS in 
those with lower 
CA125 levels. 
97 
  Platinum-resistant OC; 
comparing paclitaxel 
alone, or in combination 
with farletuzumab. 
Discontinued when 
the prespecified 
criteria for 
continuation were 
not met. 
NCT00738699 
Trastuzumab HER2-
specific 
humanized 
IgG1 
Epithelial OC; comparing 
triple or doublet 
combinations of 
trastuzumab, paclitaxel 
and carboplatin 
Ongoing trial NCT00011986 
Pertuzumab HER2-
specific 
humanized 
IgG1 
Platinum-resistant 
recurrent OC with low 
HER3 mRNA expression; 
comparing pertuzumab 
combined with topotecan 
or paclitaxel, or comparing 
placebo and pertuzumab 
combined with topotecan, 
paclitaxel or gemcitabine. 
On going trial NCT01684878 
Monoclonal antibodies targeting tumor-promoting molecules 
Bevacizumab VEGF-A- EOC, PPC and fallopian No improvement in 
126 
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specific 
humanized 
IgG1 
tube cancer; 
paclitaxel/carboplatin 
treatment combined with 
placebo, compared to 
concurrent bevacizumab, 
and concurrent plus 
maintenance bevacizumab. 
PFS with 
concurrent 
bevacizumab 
compared to 
chemotherapy, but 
increased PFS with 
concurrent plus 
maintenance 
bevacizumab. No 
difference in OS. 
  EOC; carboplatin and 
paclitaxel alone or in 
combination with 
concurrent bevacizumab. 
Improved PFS was 
observed with 
chemotherapy and 
bevacizumab 
combined. 
127 
  Platinum-resistant EOC; 
paclitaxel, PLD or 
topotecan alone, or 
combined with 
bevacizumab. 
Improved PFS with 
bevacizumab in 
combination with 
chemotherapy. 
128 
Monoclonal antibodies specific for immune targets 
Avelumab PD-L1-
specific 
human IgG1 
Platinum-resistant or 
refractory OC; comparing 
avelumab alone, combined 
with PLD, and PLD alone. 
Ongoing trial NCT02580058 
EOC, epithelial ovarian cancer; PFS, progression-free survival; OS, overall survival; trAb, trifunctional 
antibody; OC, ovarian carcinoma; PPC, primary peritoneal cancer; PLD, pegylated liposomal 
doxorubicin. 
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Table 2: Monoclonal antibodies approved for ovarian cancer treatment. 
Name Antibody FDA 
approval 
EMA approval NICE approval 
Catumaxumab EpCAM and 
CD3 bispecific 
trAb 
- Treatment of 
EpCAM-positive 
ascites 
Treatment of EpCAM-
positive ascites 
Bevacizumab VEGF-A-
specific 
humanized 
IgG1 
Treatment of 
platinum-
resistant OC 
Treatment of 
ovarian neoplasms 
i. In combination with 
carboplatin and paclitaxel 
for the treatment of 
advanced EOC  ii. In 
combination with 
carboplatin and 
gemcitabine for first 
recurrence of platinum-
sensitive EOC, FTC or 
PPC in patients not 
previously treated with 
bevacizumab or other 
VEGF-targeting agents. 
FDA, US Food and Drug Administration, www.fda.gov; EMA, European Medicines Agency, 
www.ema.europa.eu/ema; NICE, UK National Institute for Health and Care Excellence, nice.org.uk; 
trAb, trifunctional antibody; OC, ovarian carcinoma; EOC, epithelial ovarian cancer; FTC, fallopian 
tube cancer; PPC, primary peritoneal cancer. 
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Figure 1: Schematic representation of the monoclonal antibody targets for 
ovarian cancer. 
Antibodies for treatment of ovarian cancer can be targeted against tumor-associated 
antigens, tumor-promoting molecules produced and secreted in tumor environments, 
or against immune checkpoint molecules to engender immune cell activation and 
overcome immune tolerance supported by tumors. 
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